TapImmune, Aeras team on TB vaccine

TapImmune has signed a deal with non-profit development group Aeras for preclinical work on a tuberculous vaccine. TapImmune's technology is designed to make vaccines more effective by boosting antigen presentation through the use of the Transporter of Antigen Processing (TAP). Financial terms of the deal were not disclosed. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.